<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Fenofibrate decreases plasma ceramides in type 2 diabetic patients: a novel marker for CVD?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Mikaël</forename><surname>Croyal</surname></persName>
							<email>mikael.croyal@univ-nantes.fr.2</email>
							<affiliation key="aff0">
								<orgName type="laboratory">UMR 1280</orgName>
								<orgName type="institution">INRA</orgName>
								<address>
									<addrLine>Physiologie des Adaptations Nutritionnelles</addrLine>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zied</forename><surname>Kaabia</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luis</forename><surname>León</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">UMR 1280</orgName>
								<orgName type="institution">INRA</orgName>
								<address>
									<addrLine>Physiologie des Adaptations Nutritionnelles</addrLine>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stéphane</forename><surname>Ramin-Mangata</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR 1188 DéTROI</orgName>
								<orgName type="institution">INSERM</orgName>
								<address>
									<settlement>Sainte Clotilde</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Faculté de Médecine</orgName>
								<orgName type="institution">Université de La Réunion</orgName>
								<address>
									<settlement>Saint Denis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Baty</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fanta</forename><surname>Fall</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stéphanie</forename><surname>Billon-Crossouard</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">UMR 1280</orgName>
								<orgName type="institution">INRA</orgName>
								<address>
									<addrLine>Physiologie des Adaptations Nutritionnelles</addrLine>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Audrey</forename><surname>Aguesse</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">UMR 1280</orgName>
								<orgName type="institution">INRA</orgName>
								<address>
									<addrLine>Physiologie des Adaptations Nutritionnelles</addrLine>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tim</forename><surname>Hollstein</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Interdisziplinäres Stoffwechsel Centrum Arbeitsbereich Lipidstoffwechsel</orgName>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">Charité Campus Wirchow Klinikum</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">R</forename><surname>Sullivan</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">The Royal Prince Alfred Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Estelle</forename><surname>Nobecourt</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR 1188 DéTROI</orgName>
								<orgName type="institution">INSERM</orgName>
								<address>
									<settlement>Sainte Clotilde</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Faculté de Médecine</orgName>
								<orgName type="institution">Université de La Réunion</orgName>
								<address>
									<settlement>Saint Denis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">CHU de la Réunion</orgName>
								<address>
									<settlement>Saint-Pierre</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gilles</forename><surname>Lambert</surname></persName>
							<email>gilles.lambert@univ-reunion.fr</email>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR 1188 DéTROI</orgName>
								<orgName type="institution">INSERM</orgName>
								<address>
									<settlement>Sainte Clotilde</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Faculté de Médecine</orgName>
								<orgName type="institution">Université de La Réunion</orgName>
								<address>
									<settlement>Saint Denis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michel</forename><surname>Krempf</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">UMR 1280</orgName>
								<orgName type="institution">INRA</orgName>
								<address>
									<addrLine>Physiologie des Adaptations Nutritionnelles</addrLine>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">CRNHO</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">West Human Nutrition Research Center</orgName>
								<orgName type="institution" key="instit2">CHU</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Endocrinology</orgName>
								<orgName type="institution">Metabolic diseases and Nutrition, G and R Laennec Hospital</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pr</forename><surname>Gilles</surname></persName>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="laboratory">Inserm UMR 1188</orgName>
								<address>
									<settlement>Plateforme CYROI</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Rue Maxime Rivière</orgName>
								<address>
									<postCode>97490</postCode>
									<settlement>Sainte Clotilde</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Fenofibrate decreases plasma ceramides in type 2 diabetic patients: a novel marker for CVD?</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C75EFDEE78BA8514E3DED7E8058F2E5A</idno>
					<idno type="DOI">10.1016/j.diabet.2017.04.003</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:46+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Fenofibrate, type 2 diabetes, ceramide, lipidomics, apolipoprotein CVD, cardiovascular disease</term>
					<term>LDL-C, LDL-cholesterol</term>
					<term>TG, triglyceride</term>
					<term>HDL-C, HDL-cholesterol</term>
					<term>PPAR, peroxisome proliferator-activated receptor alpha</term>
					<term>ESI, electrospray ionization</term>
					<term>LC-HRMS, Liquid Chromatography-High-Resolution Mass Spectrometry</term>
					<term>m/z, mass-to-charge ratio</term>
					<term>RSD, Relative Standard Deviation</term>
					<term>S1P, sphingosine-1-phosphate</term>
					<term>Cer, Ceramide</term>
					<term>SM, Sphingomyelin</term>
					<term>IS, Internal Standard</term>
					<term>apo, apolipoprotein</term>
					<term>TC, total cholesterol</term>
					<term>S-ASM, secretory acid sphingomyelinase</term>
					<term>PCA, Principal Component Analysis</term>
					<term>OPLS, Orthogonal Projection of Latent Structures</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Aim -The benefit on cardiovascular outcomes of the lipid-lowering drug Fenofibrate is controversial.</s><s>Our aim was to find new circulating markers to identify patients susceptible to benefit from Fenofibrate prescription.</s></p><p><s>Methods -Analyses were conducted on plasma samples collected from 102 patients with type 2 diabetes before and after Fenofibrate treatment (200 mg/day) enrolled in the FIELD trial.</s></p><p><s>Non-targeted and targeted lipid analyses, and apolipoprotein measurements were achieved using mass spectrometry methods.</s></p><p><s>Results -Lipidomics revealed a global decrease in ceramides after Fenofibrate treatment confirmed by quantitative analysis (-18.2%, p &lt;0.001).</s><s>These changes were strongly associated with those measured for plasma sphingomyelin (r =0.80, p &lt;0.001) and to a lower extent with those of sphingosine-1-phosphate (r =0.34, p &lt;0.001).</s><s>Ceramide levels decreased in 73.5% of the patients.</s><s>In addition to expected lipid modulations (decrease in triglycerides, total cholesterol, LDL-cholesterol and increase in HDL-cholesterol), Fenofibrate also lowered plasma apoC-II (-11.1%,</s><s>p &lt;0.01), apoC-III (-24.6%;</s><s>p &lt;0.001), apoB100 (-27.0%,</s><s>p &lt;0.01), sphingomyelinase (-7.6%, p &lt;0.001), and increased plasma apoA-II (22.4%, p &lt;0.001) as well as adiponectin (11.4%, p &lt;0.001).</s><s>No significant association was found between ceramide decrease and these modulations except for total cholesterol (r =0.20, p =0.047) and HDL protein components.</s><s>At baseline, only elevated sphingolipid levels were significantly associated with ceramide reduction after Fenofibrate treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion -Fenofibrate lowers plasma ceramide independently of usual lipid parameters.</head><p><s>As ceramides are strong markers of atherosclerosis, our study underpins the need to further evaluate their contribution to cardiovascular events in Fenofibrate treated patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">INTRODUCTION</head><p><s>The mortality caused by cardiovascular diseases (CVD) is almost four-fold higher in diabetic patients and accounts for about 80% of diabetes-related death [1, 2].</s><s>Patients with type 2 diabetes usually present with atherogenic dyslipidemia characterized by elevated triglycerides (TG), a mild elevation of low-density lipoprotein cholesterol (LDL-C), and low high-density lipoprotein cholesterol (HDL-C) levels <ref type="bibr" target="#b2">[3]</ref>.</s></p><p><s>Fibrates target this atherogenic dyslipidemia as they increase HDL-C and decrease plasma TG and LDL-C concentrations <ref type="bibr" target="#b3">[4]</ref> via an activation of peroxisome proliferator-activated receptor alpha (PPAR), a major transcriptional regulator of lipoprotein metabolism <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s></p><p><s>Fenofibrate was one of the first marketed fibrates and was tested in two large randomized cardiovascular outcome trials in diabetic patients.</s><s>Unfortunately, both the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD-LIPID) trials <ref type="bibr" target="#b7">[7,</ref><ref type="bibr" target="#b8">8]</ref> failed to demonstrate significant benefits on cardiovascular events.</s><s>However, significant beneficial effect was observed in a subset of patients with high TG and low HDL-C [9-12], suggesting that Fenofibrate may be cardio protective in some well-selected patients.</s></p><p><s>Here, we speculated that traditional as well as novel lipid markers could explain the heterogeneity in cardiovascular response observed with Fenofibrate treatment.</s><s>To unravel potential new lipid markers of Fenofibrate treatment in a group of patients with type 2 diabetes, we performed non-targeted and targeted lipidomic approaches using several powerful mass spectrometry-based methods <ref type="bibr" target="#b14">[13]</ref><ref type="bibr" target="#b15">[14]</ref><ref type="bibr" target="#b16">[15]</ref> to explore a broad range of biochemical parameters, including lipid species and apolipoproteins <ref type="bibr" target="#b18">[16,</ref><ref type="bibr" target="#b20">17]</ref>.</s><s><ref type="bibr" target="#b4">5</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Patients and study design</head><p><s>We used plasma samples from 102 type 2 diabetic patients (males/females: 81/21, age:</s></p><p><s>62.2 ± 8.9, body mass index: 30.3 ± 5.3 kg/m²) enrolled at the Royal Prince Alfred Hospital (Sydney, Australia) for the FIELD study <ref type="bibr" target="#b22">[18]</ref>.</s><s>Briefly, plasma samples were collected after a 6-week placebo run-in period (a capsule daily at breakfast; no lipid-lowering medication) and after a 6-week active period (200 mg/day comicronized Fenofibrate) <ref type="bibr" target="#b23">[19]</ref>, and stored at -80°C until analysis.</s><s>The study was approved by the Royal Prince Alfred Hospital ethics committee, and all patients gave written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Non-targeted lipidomic analysis</head><p><s>All solvents were LC-MS grade and purchased from Biosolve (Valkenswaard, Netherlands) unless otherwise specified.</s><s>We first performed a non-targeted lipidomic analysis on a subset of paired samples (38 patients arbitrarily selected, before and after treatment, n =76 Sphingolipids were then detected by the mass spectrometer with the ESI interface operating in the positive ion mode (capillary voltage, +3 kV; desolvatation gas (N 2 ) flow and temperature, 1000 L/h and 400 °C; source temperature, 150 °C).</s><s>The multiple reaction monitoring mode was applied as described in Table <ref type="table" target="#tab_7">S2</ref> ('Appendix B', see supplementary material associated with this article online).</s><s>The linearity was expressed by the mean r² and was greater than 0.998 for all compounds (linear regression, 1/x weighting, origin excluded).</s><s>The intra-and inter-assay imprecisions of the analytical method were assessed over 4 distinct experiments ( <ref type="formula">6</ref>replicates for 4 spiked concentrations), and RSD were below 13%, 6% and 9% for Cer, SM and S1P, respectively.</s><s>Recoveries were assessed with IS and were greater than 91%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Apolipoprotein quantification</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Apolipoproteins (A-I, A-II, B100, C-I, C-II, C-III, E and M)</head><p><s>were quantified in plasma samples (30 µL) using a validated multiplexed assay involving trypsin proteolysis and subsequent analysis of proteotypic peptides by LC-MS/MS <ref type="bibr" target="#b18">[16,</ref><ref type="bibr" target="#b20">17]</ref>.</s><s>The ProteinWorks TM eXpress kit was used according to supplier's instructions (Waters Corporation) for samples preparation.</s><s>Unlabeled and labeled synthetic peptides (Thermo Scientific Biopolymers, Darmstadt, Germany) were used for standard solutions and IS, respectively.</s><s>After digestion, samples were cleaned using 30 mg Oasis HLB 1 cc Cartridges (Waters Corporation).</s><s>The cartridges were conditioned, equilibrated, loaded, washed and eluted with methanol (1 mL),</s></p><p><s>water (1 mL), samples (~200 µL), 5% methanol (1 mL) and 80% methanol (500 µL), respectively.</s><s>Eluates were dried under nitrogen, reconstituted with 100 µL of 5% actetonitrile, and 10 µL were injected into the LC-MS/MS system as described previously <ref type="bibr" target="#b18">[16]</ref> (Tables <ref type="table" target="#tab_6">S1   and S3</ref>, 'Appendix A' and 'Appendix C', see supplementary material associated with this article online).</s><s>The linearity was expressed by the mean r² which was greater than 0.995 for all compounds (linear regression, 1/x weighting, origin excluded).</s><s>The intra-and inter-assay imprecisions were assessed over 4 distinct experiments (3 replicates for 60 plasma samples), and RSD were below 9% and 12% for all apolipoproteins, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Other biochemical measurements</head><p><s>Total cholesterol (TC), TG, HDL-C and LDL-C concentrations were obtained as</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">Statistical analysis</head><p><s>Targeting a comprehensive comparison of our sample profiles originating from patients before and after treatment, unsupervised "Principal Component Analysis" (PCA) and supervised "Orthogonal Projection of Latent Structures" (OPLS) models were used with dedicated software (SIMCA-P+, Umetrics, Umea, Sweden).</s><s>The PCA model aims at giving a general overview of the main discriminations observed, whereas the OPLS model targets a supervised discrimination through the integration of a variable Y indicating the "treatment" status of the patients.</s><s>Corresponding OPLS models Volcano plot allowed visualization of the most discriminant normalized variables between pre-treated and post-treated patient samples.</s></p><p><s>Models validity was appraised using permutation tests and CV-ANOVA.</s><s>Univariate statistical analyses were performed with GraphPad Prism software (version 6.0, GraphPad Software Inc., La Jolla, CA, USA).</s><s>Results were compared using a paired t test and the parametric Pearson correlations.</s><s>Results were expressed as mean ± standard deviation and were considered statistically significant at p &lt;0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Selection of lipid markers with Fenofibrate treatment</head><p><s>From non-targeted analysis, data processing allowed the detection of 1437 variables, each characterized by a specific m/z ratio and a retention time.</s><s>All variables related to an overlapping isotopic signal were excluded and variables corresponding to a single marker detected in several adducts were added.</s><s>153 variables presented a possible match with our lipid database, based on accurate mass (± 5 ppm) and retention time (± 30 s) (Table <ref type="table">S4</ref>, 'Appendix D', see supplementary material associated with this article online).</s><s>Among these 153 lipids, 119 exhibiting a RSD value below 30% (range 0.2-27.4%) in QC samples (n =20)</s></p><p><s>were selected for multivariate analysis.</s><s>As shown in Figure <ref type="figure">1A</ref>, the non-supervised PCA model exhibited a clear discrimination between the pre-and post-treatment groups.</s><s>A supervised OPLS model was subsequently performed (R2(X) = 0.369, R2(Y) = 0.979, Q2 = 0.954, CV-ANOVA: p &lt;0.0001) and relevant markers related to Fenofibrate treatment were selected from the OPLS associated Volcano plot.</s><s>As shown in Figure <ref type="figure">1B</ref>, several markers were significantly regulated by Fenofibrate treatment.</s><s>The major result (Figure <ref type="figure">1B</ref>) was a global decrease in all variables corresponding to Cer species (i.e., 14 compounds including isomers, in red) after Fenofibrate treatment.</s><s>Five Cer species were significantly downregulated (p &lt;0.001) using multivariate analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Fenofibrate reduced plasma ceramide concentrations</head><p><s>As detailed in</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Ceramide lowering was not related to the secretory acid sphingomyelinase</head><p><s>Compared with placebo (Figure <ref type="figure">2A</ref>), Fenofibrate reduced significantly the product-to substrate ratios (Cer/SM) of S-ASM by 23.6% (p &lt;0.001).</s><s>Changes in plasma Cer and SM levels were strongly correlated (Figure <ref type="figure">2B</ref>, r = 0.800, p &lt;0.001) suggesting that both lipid families were similarly impacted by Fenofibrate treatment.</s><s>As shown in Figure <ref type="figure">2C</ref>, Fenofibrate slightly but significantly reduced S-ASM plasma concentrations by 7.6% (131.2 ± 32.0 ng/mL vs 121.2 ± 27.8 ng/mL, p &lt;0.001), but these changes were not significantly associated with the Cer/SM ratios (Figure <ref type="figure">2D</ref>, r = -0.146,</s><s>p =0.124).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Effect of Fenofibrate on other plasma lipids and apolipoproteins</head><p><s>As previously reported (</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Ceramide associations with plasma lipids and apolipoproteins</head><note type="other">After</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">DISCUSSION</head><p><s>In this study, we investigated modifications in the lipidomic profiles of type 2 diabetic patients treated with Fenofibrate.</s><s>The non-targeted lipidomic approach unravels a global decrease in plasma ceramides (Cer), subsequently confirmed by accurate quantitative assay.</s></p><p><s>Fenofibrate also increased plasma apolipoproteins related to HDL metabolism, and decreased those related to triglyceride-rich lipoprotein metabolism.</s><s>Here, Fenofibrate reduced plasma secretory acid sphingomyelinase (S-ASM) and related product-to-substrate ratio (i.e., Cer/SM).</s><s>However these changes were not correlated and S-ASM changes did not appear to be the main factor related to the decrease of plasma Cer synthesis in the circulation.</s><s>Plasma Cer reductions were only associated with elevated baseline levels of plasma Cer, SM, and S1P.</s><s>SPT is strongly increased in hypertriglyceridemia [31] and we showed a significant association between Cer modulation and elevated baseline levels of TG in the subset of patients in whom Cer levels were reduced by Fenofibrate.</s><s>It might be speculated that Fenofibrate could act on the SPT reaction, a rate-limiting step in the de novo synthesis of Cer <ref type="bibr" target="#b42">[29]</ref>, but this is unlikely since changes in Cer did not significantly correlate with changes in TG levels in these patients.</s></p><p><s>Noteworthy, we did not observe any correlation with the increase of adiponectin known to be an independent stimulator of ceramidase leading to the conversion of Cer into S1P There are some limitations in this study.</s><s>We have restricted the non-targeted lipidomic approach to known lipid compounds of our database, potentially neglecting some interesting but uncharacterized compounds.</s><s>Accurate analysis of a more complete set of variables should therefore provide additional insights into the efficacy of Fenofibrate.</s><s>It must also be underlined that the number of patients was small and that evaluation of Cer decrease on cardiovascular events was thus not feasible.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">CONCLUSION</head><p><s>In summary, we showed that Fenofibrate reduced plasma Cer in type 2 diabetic patients, especially in those presenting with high baseline Cer levels.</s><s>This modulation did not appear related to their lipoprotein profile, even when patients were stratified by baseline lipid levels.</s></p><p><s>Our study therefore indicates that Cer could be an independent marker of CVD in type 2</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>described previously [ 18 ]</head><label>18</label><figDesc><div><p><s>and non-HDL cholesterol (non-HDL-C) concentrations were calculated.</s><s>Secretory acid sphingomyelinase (S-ASM) and adiponectin concentrations were measured in plasma samples using two commercial ELISA kits according to the manufacturer's instructions (Cloud-Clone Corp., Houston, TX, USA and Adipogen Corporation, San Diego, CA, USA, respectively).</s><s>HDL particles diameters were estimated using the updated Shen's model as follows [23]: HDL diameter (nm) = 4.66 + 12.31 × [HDL-C/(apoA-I+apoA-II)] with HDL-C, apoA-I and apoA-II in mg/dL.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Fenofibrate treatment, the decrease in plasma Cer levels was significantly associated with changes in TC (r =0.203, p =0.047), S1P (r =0.34, p &lt;0.001), apoA-I (r =0.26, p =0.011), apoA-II (r =0.21, p =0.045), and apoM (r =0.24, p =0.018).</s><s>No association was found between plasma S-ASM changes and any lipid species or HDL particles size.</s><s>Neither did we find a correlation between plasma Cer and non-HDL-C, plasma TG and plasma apoB100.</s><s>Changes in Cer were found similar when patients were stratified by elevated non-HDL-C (&gt; 3.36 mmol/L) or TG (&gt; 2.33 mmol/L) levels, or low HDL-C (&lt; 0.88 mmol/L) or LDL-C (&lt; 2.59 mmol/L) levels as described in studies showing significant beneficial effects in these subgroups [9-12].</s><s>As shown in Figure3, significant inverse correlations were found between the decrease of Cer and baseline levels of plasma Cer (r =-0.52, p &lt;0.001), SM (r =-0.37, p &lt;0.001), S1P (r =-0.27, p =0.01) and S-ASM (r =-0.22,</s><s>p =0.034) concentrations, whereas no association was found between the reductions in plasma Cer and basal levels of apolipoproteins, adiponectin or other plasma lipids.</s><s>Noteworthy, in the subset of patients in whom Cer levels were reduced by Fenofibrate (n =75), we found a significant correlation between Cer modulation and baseline levels of TG (r =-0.34, p =0.004).</s><s>However, we did not find any association between Cer and TG modulations in the subset of patients (n = 50) with elevated baseline TG levels (&gt; 1.7 mmol/L or 150 mg/dL).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>2 diabetes [ 24 , 25 ]</head><label>22425</label><figDesc><div><p><s>Sphingolipids and especially Cer appear to be important bioactive lipids involved in type and atherosclerosis [26, 27].</s><s>Recently, Cer were independently associated with fatal outcome of coronary artery disease, and their predictive value was shown to be superior to that of LDL-C [28].</s><s>Cer play a central role in sphingolipid metabolism and their synthesis requires the activation of serine-palmitoyl transferase (SPT) [29].</s><s>After synthesis into the liver, Cer can be either converted to sphingomyelin (SM) or catabolized to sphingosine and then sphingosine-1-phosphate (S1P).</s><s>Following hepatic synthesis, SM are incorporated to very-low-density lipoprotein (VLDL) for secretion into the circulation where 13 sphingomyelinases can convert them back into Cer.</s><s>The availability of SM for transport on lipoproteins depends on SPT.</s><s>Alternatively, adiponectin can stimulate ceramidase activity in the liver, thus enhancing the conversion of Cer into S1P, independently of other effects on lipid metabolism [30].</s><s>Thus, Cer reduction measured after Fenofibrate treatment could be either related to a direct impact on hepatic (SPT, ceramidase) or circulating (sphingomyelinase) synthesis, but also indirectly related to a carrier effect (VLDL) due to changes in circulating lipoprotein levels.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>9</head><label>9</label><figDesc><div><p></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2 - 15 Figure 3 - 17 ( 18 (</head><label>21531718</label><figDesc><div><p><s>Figure 2 -Associations between ceramides (Cer) and sphingomyelins (SM) changes into</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>20]. 2.3. Quantification of sphingolipids in plasma</head><label></label><figDesc><div><p><s>LC-MS/MS) analyses.</s><s>LC-MS/MS analyses were performed on a Xevo ® TQD mass spectrometer with an ESI interface and an Acquity H-Class ® UPLC TM device (Waters Corporation).</s><s>Data acquisition and analyses were performed with MassLynx ® and TargetLynx ® software, respectively (version 4.1, Waters Corporation).</s><s>Samples (10 µL) were injected onto a reversed-phase LC column and compounds were separated as indicated in</s></p></div></figDesc><table><row><cell>(d18:1/17:0), 500 nmol/L; S1P d17:1, 500 nmol/L and SM (d18:1/17:0), 5 µmol/L]. Samples</cell></row><row><cell>were mixed and centrifuged 10 min at 20,000 × g (10 °C). Supernatants were dried under a</cell></row><row><cell>(mass-to-charge ratio (m/z) range 50-1,200) at a mass resolution of 25,000 full-widths at half nitrogen stream and solubilized in 100 µL of methanol for liquid chromatography-tandem</cell></row><row><cell>maximum. The ionization settings were as follows: capillary voltage, +2 kV; cone voltage, 30 mass spectrometry (</cell></row><row><cell>V; desolvation gas (N 2 ) flow rate, 900 L/h; desolvation gas/source temperatures, 550/120 °C.</cell></row><row><cell>Leucine enkephalin solution (2 µg/mL, 50% acetonitrile) was infused at a constant flow rate</cell></row><row><cell>of 10 µL/min in the lockspray channel, allowing for correction of the measured m/z</cell></row><row><cell>throughout the batch (theoretical m/z 556.2771 in positive mode). Data acquisition and</cell></row><row><cell>processing were achieved using MassLynx ® and MakerLynx ® software (version 4.1, Waters</cell></row><row><cell>Corporation). Lipid markers were extracted from the detected variables using an in-house</cell></row><row><cell>database containing reference lipid standards (exact mass measured ± 5 ppm, elemental</cell></row><row><cell>compositions, retention times, fragmentation patterns) [21, 22]. Simultaneously, QC sample</cell></row><row><cell>analyses were executed to evaluate the analytical system performance during the run. The</cell></row><row><cell>relative standard deviation (RSD, %) was calculated for QC variables peak areas to evaluate</cell></row><row><cell>their analytical quality and robustness. Finally, lipid markers having a RSD value below 30%</cell></row><row><cell>in QC samples were kept for subsequent multivariate analysis [A pool of reference standard solutions, including sphingosine-1-phosphate (S1P d18:1), 9</cell></row><row><cell>ceramide (Cer) species and 9 sphingomyelin (SM) species (Avanti Polar, Coger, Paris,</cell></row><row><cell>France; Table S2, 'Appendix B', see supplementary material associated with this article</cell></row><row><cell>online), was prepared and then serially diluted in methanol to obtain 7 standard solutions</cell></row><row><cell>ranging 1-500 nmol/L, 2-1000 nmol/L and 0.04-20 µmol/L for Cer, S1P, and SM,</cell></row><row><cell>respectively. Standard solutions and plasma samples (10 µL) were then extracted with 500 µL</cell></row><row><cell>of methanol/chloroform mixture (2/1, v/v) containing exogenous internal standards [IS; Cer</cell></row></table><note><p><s>[20]uality control (QC) samples were used as previously indicated[20].To constitute the QC samples, 10 µL of each plasma sample (n =76) were collected and pooled before to be split in twenty aliquots of 25 µL.Lipids were extracted from plasma and QC samples(25 µL)with 500 µL of a methanol/chloroform mixture (2/1, v/v).Following centrifugation at 20,000 × g (10°C) for 10 min, supernatants were collected and dried under nitrogen, then solubilized in 100 μL of a isopropanol/acetonitrile/water mixture (2/1/1, v/v/v).Samples were arbitrarily randomized before analysis [20] by liquid chromatography-high resolution mass spectrometry (LC-HRMS).LC-HRMS analyses were performed on a Synapt TM G2 HRMS Q-TOF mass spectrometer equipped with an electrospray ionization (ESI) interface operating in the positive mode and an Acquity H-Class ® UPLC TM device (Waters Corporation, Milford, MA, USA).Samples and QC extracts were injected (10 µL) onto a reversed-phased LC column and lipids were eluted as detailed in TableS1('Appendix A', see supplementary material associated with this article online).</s><s>The full-HRMS mode was applied for lipid detection</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table S1</head><label>S1</label><figDesc></figDesc><table /><note><p><s>('Appendix A', see supplementary material associated with this article online).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 ,</head><label>1</label><figDesc><div><p><s>both Cer and SM species were quantified in the entire set of paired</s></p></div></figDesc><table /><note><p><s>plasma samples (102 patients before and after treatment).Seven Cer species were detected in plasma and significantly decreased (-11.4% to -20.2%; p &lt;0.05) by Fenofibrate treatment.In comparison with placebo, Fenofibrate reduced total plasma Cer levels by 18.2% (p &lt;0.001).Cer reduction was observed for 73.5% of patients (n =75, FigureS1, 'Appendix E', see supplementary material associated with this article online).</s><s>Although 4 out of 9 SM species detected in plasma were significantly altered (either increased or decreased significantly), Fenofibrate did not significantly affect total plasma SM levels (p =0.366).</s><s>Neither did Fenofibrate modulate plasma S1P concentrations (1.07 ± 0.34 µmol/L vs 1.04 ± 0.33 µmol/L for placebo, respectively; p =0.377).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>), Fenofibrate decreased TC by 11.3% (p &lt; 0.001), LDL-C</cell></row><row><cell>by 12.8% (p &lt;0.001), non-HDL-C by 12.9% (p &lt;0.001) and TG by 30.7% (p &lt;0.001), while</cell></row><row><cell>HDL-C increased by 5.7% (p &lt;0.01). In addition, Fenofibrate increased plasma adiponectin</cell></row><row><cell>by 11.4% (p &lt;0.001), apoA-II by 22.4% (p &lt;0.001), and apoM by 7.8% (p =0.016), but</cell></row><row><cell>decreased plasma apoB100 by 27.0% (p &lt;0.001), apoC-I by 12.9% (p =0.050), apoC-II by</cell></row><row><cell>11.1% (p =0.005), and apoC-III by 24.6% (p &lt;0.001). No significant modulation was</cell></row></table><note><p><s>observed for plasma apoE (-7.9%, p =0.058) and apoA-I (6.1%, p =0.104).As expected, several associations were observed between plasma lipids and apolipoproteins (TableS5, 'Appendix F', see supplementary material associated with this article online).</s><s>Of</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>note, Fenofibrate treatment did not affect significantly the size of HDL particles (8.3 ± 0.9 vs 8.3 ± 1.0 nm for placebo, respectively; p =0.970).</head><label></label><figDesc></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>[30].</head><label></label><figDesc><div><p><s>[35][36][37]ons could be related to enhanced VLDL catabolism, an effect likely mediated by reductions in apoC-III[33]and/or by an increase in adiponectin[34].It is known that Fenofibrate reduces VLDL levels by accelerating their catabolism[35][36][37].</s><s>Here, Fenofibrate significantly increased adiponectin and reduced apoC-III, but no correlation could be made between changes in both apoC-III and adiponectin and changes in Cer, so it is unlikely that Fenofibrate mediated Cer reductions might result from lower level of VLDL.</s></p></div></figDesc><table><row><cell>that</cell></row><row><cell>Fenofibrate is a PPARagonist and acts on lipoprotein metabolism [5, 6]. Thus, the</cell></row><row><cell>reduction of plasma Cer observed in our study could result from changes in lipoprotein</cell></row><row><cell>secretion and/or catabolism. The variations measured in apolipoprotein plasma concentrations</cell></row><row><cell>could support this hypothesis but no correlation was found between plasma Cer and</cell></row><row><cell>apolipoprotein variations except for HDL components. In that respect, Rosuvastatin also</cell></row><row><cell>reduced Cer concentrations, which paralleled reductions in VLDL levels [32]. This suggests</cell></row><row><cell>14</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 1 -</head><label>1</label><figDesc><div><p><s>Mean ± standard deviation of ceramide and sphingomyelin concentrations measured in plasma.</s><s>A paired t test was used for group</s></p></div></figDesc><table><row><cell cols="6">comparisons (*, p &lt;0.05; **, p &lt;0.01; ***, p &lt;0.001). BLOD: below the limit of detection, NA: not applicable.</cell><cell></cell></row><row><cell></cell><cell cols="2">Plasma Ceramide (nmol/L)</cell><cell></cell><cell cols="2">Plasma sphingomyelin (µmol/L)</cell><cell></cell></row><row><cell>Fatty acyl</cell><cell>Placebo</cell><cell>Fenofibrate</cell><cell>Fold Change</cell><cell>Placebo</cell><cell>Fenofibrate</cell><cell>Fold Change</cell></row><row><cell>C16:0</cell><cell>0.11 ± 0.05</cell><cell>0.09 ± 0.04</cell><cell>-19.4% ***</cell><cell>96.5 ± 21.5</cell><cell>98.4 ± 23.0</cell><cell>+2.0%</cell></row><row><cell>C18:0</cell><cell>0.14 ± 0.07</cell><cell>0.12 ± 0.05</cell><cell>-19.7% ***</cell><cell>13.0 ± 3.5</cell><cell>12.1 ± 3.2</cell><cell>-7.5% **</cell></row><row><cell>C18:1</cell><cell>BLOD</cell><cell>BLOD</cell><cell>NA</cell><cell>7.1 ± 1.9</cell><cell>7.0 ± 2.1</cell><cell>-2.0%</cell></row><row><cell>C20:0</cell><cell>0.10 ± 0.04</cell><cell>0.09 ± 0.04</cell><cell>-15.0% **</cell><cell>75.4 ± 20.8</cell><cell>70.9 ± 20.1</cell><cell>-6.0% *</cell></row><row><cell>C20:1</cell><cell>BLOD</cell><cell>BLOD</cell><cell>NA</cell><cell>3.0 ± 0.7</cell><cell>2.9 ± 0.7</cell><cell>-3.6%</cell></row><row><cell>C22:0</cell><cell>2.46 ± 1.19</cell><cell>2.02 ± 0.82</cell><cell>-17.7% ***</cell><cell>64.5 ± 18.4</cell><cell>67.5 ± 20.6</cell><cell>+4.6%</cell></row><row><cell>C22:1</cell><cell>0.03 ± 0.02</cell><cell>0.03 ± 0.01</cell><cell>-11.4% *</cell><cell>24.1 ± 6.2</cell><cell>23.6 ± 6.9</cell><cell>-1.9%</cell></row><row><cell>C24:0</cell><cell>0.47 ± 0.21</cell><cell>0.41 ± 0.16</cell><cell>-14.0% **</cell><cell>45.0 ± 16.0</cell><cell>50.4 ± 19.7</cell><cell>+12.1 **</cell></row><row><cell>C24:1</cell><cell>1.73 ± 0.78</cell><cell>1,279 ± 537.6</cell><cell>-20.2% ***</cell><cell>73.1 ± 19.5</cell><cell>78.7 ± 23.0</cell><cell>+7.8% *</cell></row><row><cell>TOTAL</cell><cell>5.05 ± 2.20</cell><cell>4.13 ± 1.50</cell><cell>-18.2% ***</cell><cell>401.7 ± 95.5</cell><cell>411.5 ± 107.7</cell><cell>+2.4%</cell></row></table><note><p><s><ref type="bibr" target="#b16">15</ref>8,38,39]atients, as previously suggested for non-diabetics[28,38,39].As Cer appear to be involved in type-2 diabetes and atherosclerosis [24, 26, 27], our study underlines the need to evaluate their predictive value on the onset of cardiovascular events in those patients.15</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2 -</head><label>2</label><figDesc><div><p><s>Mean ± standard deviation of plasma lipids before and after Fenofibrate treatment.A paired t test was used for group comparisons (* p &lt;0.05; ** p &lt;0.01; *** p &lt;0.001).</s></p></div></figDesc><table><row><cell>2</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Parameters</cell><cell>Placebo</cell><cell>Fenofibrate</cell><cell>Fold Change</cell></row></table><note><p><s>1 1 Figure 1 -Lipidomics</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>unravels ceramides as new potential lipid markers of Fenofibrate</head><label></label><figDesc><div><p><s>Principal component analysis (PCA) model based on identified lipids (n 3 =119) from the lipid fingerprints of human plasma samples (placebo versus Fenofibrate, n Volcano plot representation highlighting major lipid class differences associated with 6 treatment, namely ceramide species (red dots) and additional significant lipids labeled (PC,</s></p></div></figDesc><table><row><cell>4</cell><cell></cell></row><row><cell>5</cell><cell>=38 per group). (B) Orthogonal Projection of Latent Structures (OPLS) corresponding</cell></row></table><note><p><s>2 efficiency.</s><s>(A) 7 phosphatidylcholine; PG, phosphatidylglycerol; TG, triglyceride; DG, diglyceride; VIP, 8 variable importance of projection).</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDMENTS</head><p><s>We are grateful to the Biogenouest CORSAIRE core facility for financial support.</s><s>GL is the recipient of an Allocation de Recherche Chaire-Mixte (Inserm-Université de La Réunion), and a Programme de Recherche Hospitalière en Santé ANR-16-RHUS-0007.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCLOSURE OF INTEREST</head><p><s>The authors declare that they have no competing interest.</s><s><ref type="bibr" target="#b18">16</ref></s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Lipids, diabetes, and coronary heart disease: insights from the Framingham Study</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Kannel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1100" to="1107" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Stamler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Vaccaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Neaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wentworth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="434" to="444" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Use of fibrates in the metabolic syndrome: A review</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Shipman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Strange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramachandran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="74" to="88" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing</title>
		<author>
			<persName><forename type="first">M</forename><surname>Farnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vasc Health Risk Manag</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="991" to="1000" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Peroxisome proliferator activated receptors and lipoprotein metabolism</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kersten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PPAR Res</title>
		<imprint>
			<biblScope unit="page">132960</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia</title>
		<author>
			<persName><surname>Ppar-Α</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PPAR Res</title>
		<imprint>
			<biblScope unit="page">924131</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Keech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Simes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Taskinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Forder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pillai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Glasziou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Drury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Kesäniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Colman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Emden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Whiting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ehnholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laakso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="1849" to="1861" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Effects of combination lipid therapy in type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Elam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Lovato</surname></persName>
		</author>
		<author>
			<persName><surname>Crouse Jr 3rd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Leiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Linz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Friedewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Buse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Probstfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ismail-Beigi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Bigger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Goff</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Simons-Morton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Byington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="1563" to="1574" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Effects of fibrates on cardiovascular outcomes: a systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Foote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Nicholls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Grobbee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chalmers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Perkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1875" to="1884" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zannino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laakso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Kesäniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Sy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Keech</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">17</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study</title>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="92" to="99" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bruckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Labreuche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Deplanque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Touboul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Amarenco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Pharmacol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="267" to="272" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Elam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Lovato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Corson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Largay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Leiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Sweeney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Friedewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Buse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Probstfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ismail-Beigi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Goff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Fleg</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Byington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename></persName>
		</author>
		<idno type="DOI">10.1001/jamacardio.2016.4828</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Cardiol</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Lipidomics as a principal tool for advancing research</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><surname>Shui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Genet Genomics</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="375" to="390" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Lipidomics for studying metabolism</title>
		<author>
			<persName><forename type="first">X</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Endocrinol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="668" to="679" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">O</forename><surname>Quehenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Armando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Milne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Merrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bandyopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Shaner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Sullards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Barkley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Leiker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Raetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Laird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Six</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mcdonald</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Lipidomics reveals a remarkable diversity of lipids in human plasma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Subramaniam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fahy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Dennis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Lipid Res</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="3299" to="3305" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Croyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ferchaud-Roucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chétiveaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zaïr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ouguerram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Krempf</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS</title>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Nobécourt</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Lipid Res</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="509" to="515" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Tavori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Christian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Minnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Plubell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yeang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Giunzioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Croyal</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">PCSK9 Association With Lipoprotein(a)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Duell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tsimikas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="29" to="35" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment</title>
		<author>
			<persName><forename type="first">G</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ancellin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Charlton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Comas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pilot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Keech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Cohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Rye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Barter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1038" to="1045" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Forder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Taskinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Keech</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>FIELD Study Investigators</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate</title>
		<imprint>
			<biblScope unit="volume">64783481</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Broadhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Begley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zelena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Francis-Mcintyre</surname></persName>
		</author>
		<imprint>
			<pubPlace>Anderson N, Brown</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry</title>
		<author>
			<persName><forename type="first">M</forename><surname>Knowles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Halsall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haselden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Nicholls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Kell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Goodacre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Protoc</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1060" to="1083" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Gallart-Ayala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Courant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Severe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Antignac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Morio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abadie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Bizec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Versatile lipid profiling by liquid chromatography-high resolution mass spectrometry using all ion fragmentation and polarity switching. Preliminary application for serum samples phenotyping related to canine mammary cancer</title>
	</analytic>
	<monogr>
		<title level="j">Anal Chim Acta</title>
		<imprint>
			<biblScope unit="volume">796</biblScope>
			<biblScope unit="page" from="75" to="83" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Comprehensive blood plasma lipidomics by liquid chromatography/quadrupole time-of-flight mass spectrometry</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pereira Ados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vanhoenacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sandra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Chromatogr A</title>
		<imprint>
			<biblScope unit="volume">1217</biblScope>
			<biblScope unit="page" from="4087" to="4099" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the women&apos;s health study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Mazer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Giulianini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Paynter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mora</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="949" to="958" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Boon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Meex</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Henstridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Meikle</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Horowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Kingwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Watt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="401" to="410" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Haus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kashyap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kasumov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Defronzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kirwan</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance</title>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="337" to="343" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suoniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kardys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vihervaara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Akkerhuis</surname></persName>
		</author>
		<author>
			<persName><surname>Sysi-Aho</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Ekroos</forename><forename type="middle">K</forename><surname>Garcia-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Oemrawsingh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Regar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Koenig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Serruys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Geuns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Boersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laaksonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">243</biblScope>
			<biblScope unit="page" from="560" to="566" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Ceramide: a common pathway for atherosclerosis?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bismuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="497" to="504" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Tarasov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ekroos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suoniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kauhanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sylvänne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hurme</surname></persName>
		</author>
		<imprint>
			<pubPlace>Gouni-Berthold</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency</title>
		<author>
			<persName><forename type="first">I</forename><surname>Berthold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Kleber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Laaksonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>März</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="E45" to="52" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/-mice fed on a high-fat diet</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Deevska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sunkara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Nikolova-Karakashian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biosci Rep</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="479" to="490" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">V</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Barth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Bui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Bikman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Halberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rutkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Tenorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Brozinick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Birnbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Scherer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="55" to="63" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Dietary soy protein reduces cardiac lipid accumulation and the ceramide concentration in high-fat diet-fed rats and ob/ob mice</title>
		<author>
			<persName><forename type="first">Torre-Villalvazo I</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Aguilar-Salinas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Tovar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="2237" to="2243" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Ooi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Meikle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Barrett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2497" to="2501" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Dosedependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Ooi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Nestel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sviridov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Barrett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1656" to="1661" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Farvid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Barrett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="795" to="802" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">J</forename><surname>Serone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Croft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Loehrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="803" to="811" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL-and LDL-ApoB kinetics in type 2 diabetes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Vergès</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Florentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baillot-Rudoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Monier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Petit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rageot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Duvillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1382" to="1390" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ouguerram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Magot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zaïr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Marchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Charbonnel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Laouenan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krempf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="332" to="337" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Sigruener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kleber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heimerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liebisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Maerz</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study</title>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e85724</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Laaksonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ekroos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sysi-Aho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hilvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vihervaara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kauhanen</surname></persName>
		</author>
		<author>
			<persName><surname>Suoniemi</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol</title>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Hurme</forename><forename type="middle">R</forename><surname>März</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Scharnagl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stojakovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vlachopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lokki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Nieminen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Klingenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Matter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hornemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jüni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rodondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Räber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Tell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Nygård</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sinisalo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lüscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1967" to="1976" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m">TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 3 lipoprotein cholesterol; non-HDL-C, non-HDL cholesterol; TG, triglyceride; Apo</title>
				<imprint>
			<biblScope unit="page">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
